
RECEIVED CENTRAL FAX CENTER

FAX

JUL 2 8 2006





GlaxoSmithKline PO Box 13398 Five Moore Drive Research Triangle Park North Carolina 27709

Tel: 919 483 2100 www.gsk.com

Attached: Response under 37 C.F.R. §1.111 (27 pgs.)

The information contained in these documents is confidential and may also be privileged and is intended for the exclusive use of the addressee designated above. If you are not the intended recipient or the employee or agent responsible to deliver it to the intended recipient, any disclosure, reproduction, distribution, or any other dissemination or use of this communication is strictly prohibited. If you have received this transmission in error please contact us immediately by telephone so that we can arrange for its return.

919 483 7977

To:USPTO

P.2 🗸

Serial No. 10/070,084 Dicket No. PU3517USw Reply to Office Action of March 30, 2006

RECEIVED CENTRAL FAX CENTER

5

JUL 2 8 2006

Docket No. PU3517USw

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: Andrews, C.W. et al.

SERIAL NO. 10/070,084 ART UNIT: 1624

FILED: March 7, 2002

EXAMINER: Deepak R. Rao

FOR:

BENZOPHENONES AS INHIBITORS OF REVERSE TRANSCRIPTASE

Commissioner of Patents P.O. Box 1450 Alexandria VA 22313-1459

Response under 37 C.F.R. § 1.111

Sir:

This Amendment is in response to the Office Action dated March 30, 2006 for which the period for response expired on June 30, 2006. Applicant hereby requests a 1 (one)-month extension of time to extend the response period up to and including July 30, 2006. Please charge Deposit Account No. 07-1392 in the amount of \$120.00.

In response to the Office action mailed March 30, 2006, please amend the aboveidentified application as follows:

Amendments to the Claims are reflected in the listing of claims which begins on page 2 of this paper.

Remarks begin on page 25 of this paper.

07/31/2086 BABRAHAI 09088014 071392 19070084

01 FC:1251 120.00 DA